Millions of people worldwide are currently concerned by age-related diseases. This number is likely to increase exponentially as the population continues to age: according to the World Health Organisation “By 2050, the world’s population aged 60 years or older is expected to total 2 billion”Age-related diseases have a tremendous impact on individuals, families and societies. International organisations recognise healthy ageing for all citizens as a main priority. With the aim to meet this challenge, we decided to identify and investigate innovative therapeutic strategies to provide long-term solutions for patients suffering from age-related neurodegenerative diseases for which only few to no treatments exist.  

brain-big data

We believe that the exponential advances in the booming sector of in silico analyses and artificial intelligence (AI) combined with new insights into the pathophysiology of neurodegenerative diseases create a breakthrough opportunity to accelerate the discovery of New Chemical Entities (NCE) and repositioning molecules which will provide long-term therapeutic solutions for patients suffering from Alzheimer’s disease, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal lobar degeneration (FTLD).  

Considering that multi-factorial molecular mechanisms lead to the neurodegeneration onset, our approach is to identify repositioning drugs and combination targeting early mechanisms involved in the disease onsetonset or early stage of the disease.